Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study
Rinkoo Dalan, Li Wei Ang, Wilnard Yeong Tze Tan, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2020) Vol. 7, Iss. 3, pp. e48-e51
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Soo Lim, Jae Hyun Bae, Hyuk‐Sang Kwon, et al.
Nature Reviews Endocrinology (2020) Vol. 17, Iss. 1, pp. 11-30
Open Access | Times Cited: 936
Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning
Daniel J. Drucker
Cell Metabolism (2021) Vol. 33, Iss. 3, pp. 479-498
Open Access | Times Cited: 241
Statin use is associated with lower disease severity in COVID-19 infection
Wilnard Yeong Tze Tan, Barnaby Edward Young, David Chien Lye, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 110
Risk phenotypes of diabetes and association with COVID-19 severity and death: a living systematic review and meta-analysis
Sabrina Schlesinger, Manuela Neuenschwander, Alexander Lang, et al.
Diabetologia (2021) Vol. 64, Iss. 7, pp. 1480-1491
Open Access | Times Cited: 94
Diabetes and COVID-19: The past, the present, and the future
Raymond Pranata, Joshua Henrina, Wilson Matthew Raffaello, et al.
Metabolism (2021) Vol. 121, pp. 154814-154814
Open Access | Times Cited: 87
COVID-19 and Diabetes
Awadhesh Kumar Singh, Kamlesh Khunti
Annual Review of Medicine (2021) Vol. 73, Iss. 1, pp. 129-147
Closed Access | Times Cited: 81
Diabetes and COVID-19; A Bidirectional Interplay
Paraskevi Kazakou, Vaia Lambadiari, Ignatios Ikonomidis, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 66
Comparable COVID‐19 outcomes with current use of GLP‐1 receptor agonists, DPP‐4 inhibitors or SGLT‐2 inhibitors among patients with diabetes who tested positive for SARS‐CoV‐2
Simone Bastrup Israelsen, Anton Pottegård, Håkon Sandholdt, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 6, pp. 1397-1401
Open Access | Times Cited: 59
COVID-19: Diabetes Perspective—Pathophysiology and Management
Siva Dallavalasa, SubbaRao V. Tulimilli, Prakash Janhavi, et al.
Pathogens (2023) Vol. 12, Iss. 2, pp. 184-184
Open Access | Times Cited: 24
Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis
Tiantian Han, Shaodi Ma, Chenyu Sun, et al.
Archives of Medical Research (2021) Vol. 53, Iss. 2, pp. 186-195
Open Access | Times Cited: 50
Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis
Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini
Journal of Endocrinological Investigation (2021) Vol. 44, Iss. 7, pp. 1379-1386
Open Access | Times Cited: 44
The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis
Yidan Chen, Xingfei Lv, Sang Lin, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 34
Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors
Mei‐Zhen Wu, Chanchal Chandramouli, Pui‐Fai Wong, et al.
Diabetes & Metabolism (2022) Vol. 48, Iss. 6, pp. 101367-101367
Open Access | Times Cited: 30
Renin–angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies
Chirag Bavishi, Paul K. Whelton, Giuseppe Mancia, et al.
Journal of Hypertension (2021) Vol. 39, Iss. 4, pp. 784-794
Open Access | Times Cited: 41
Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis
Rimesh Pal, Mainak Banerjee, Soham Mukherjee, et al.
Therapeutic Advances in Endocrinology and Metabolism (2021) Vol. 12
Open Access | Times Cited: 39
Perspectives of Antidiabetic Drugs in Diabetes With Coronavirus Infections
Bao Sun, Shiqiong Huang, Jiecan Zhou
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 34
Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis
Sabrina Schlesinger, Alexander Lang, Nikoletta Christodoulou, et al.
Diabetologia (2023) Vol. 66, Iss. 8, pp. 1395-1412
Open Access | Times Cited: 16
Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis
Syed Shahzad Hasan, Chia Siang Kow, Muhammad Abdul Hadi, et al.
American Journal of Cardiovascular Drugs (2020) Vol. 20, Iss. 6, pp. 571-590
Open Access | Times Cited: 39
Update Alert: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults
Devan Kansagara, Katherine Mackey, Kathryn Vela
Annals of Internal Medicine (2020) Vol. 173, Iss. 3, pp. W66-W66
Open Access | Times Cited: 34
Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature
Awadhesh Kumar Singh, Ritu Singh, Banshi Saboo, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2020) Vol. 15, Iss. 1, pp. 159-167
Open Access | Times Cited: 34
Sodium-glucose co-transporter 2 inhibitors in COVID-19: meeting at the crossroads between heart, diabetes and infectious diseases
Theocharis Koufakis, Antonis N. Pavlidis, Symeon Metallidis, et al.
International Journal of Clinical Pharmacy (2021) Vol. 43, Iss. 3, pp. 764-767
Open Access | Times Cited: 30
Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19? – Targeting hyperinflammation
Afnan Alshnbari, Iskandar Idris
Current Medical Research and Opinion (2022) Vol. 38, Iss. 3, pp. 357-364
Open Access | Times Cited: 20
Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock
Hang‐Long Li, Yi-Kei Tse, Chanchal Chandramouli, et al.
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 107, Iss. 12, pp. 3442-3451
Open Access | Times Cited: 20
Diabetes as one of the long-term COVID-19 complications: from the potential reason of more diabetic patients’ susceptibility to COVID-19 to the possible caution of future global diabetes tsunami
Yasamin Sharbatdar, Ronak Mousavian, Seyed Mostafa Noorbakhsh Varnosfaderani, et al.
Inflammopharmacology (2023) Vol. 31, Iss. 3, pp. 1029-1052
Open Access | Times Cited: 13
Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research
Jordan Loader, Frances Taylor, Erik Lampa, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 11
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top